Cocrystal Advances Norovirus Antiviral CDI-988 with Phase 1b Human Challenge Study
Event summary
- Cocrystal presented Phase 1b human challenge study data for CDI-988 at ICAR 2026, highlighting its mechanism of action against norovirus.
- The ongoing Phase 1b study is designed to demonstrate proof-of-concept as a preventive and treatment for norovirus infection.
- CDI-988 has received FDA Fast Track designation due to the lack of approved therapies for norovirus.
- Norovirus causes an estimated $60 billion annual economic burden globally.
The big picture
Cocrystal's progress with CDI-988 addresses a critical gap in antiviral therapies, as norovirus remains the leading cause of acute gastroenteritis without approved treatments. The Phase 1b study's success could position CDI-988 as a key player in preventing and treating outbreaks, particularly in high-risk environments like hospitals and cruise ships.
What we're watching
- Clinical Efficacy
- How the Phase 1b study results will validate CDI-988's effectiveness in preventing and treating norovirus infection.
- Regulatory Pathway
- Whether the FDA Fast Track designation will expedite CDI-988's approval process.
- Market Potential
- The pace at which Cocrystal can commercialize CDI-988 given the unmet need for norovirus treatments.
Related topics